SIOGEN Biotech is an innovative and dynamic biotech company, positioning itself globally in the new and exciting area of drug targeting and delivery, with an ever increasing network of strategic partnerships all around the globe. Equipped with its proprietary cutting-edge drug delivery platform called Siosomes® (based on Silane molecules), the company is focusing on the commerciali sation of its nanotechnology for the improvement and development of medical drugs. The platform technology provides added benefits to drugs such as enhanced efficacy, decreased toxicity, alternative routes of administration, and lower dose of administration. This ultimately translates to lower treatment costs and better treatment management for patients. Siosomes® can also be used to modulate the immune system in immunotherapy applications, such as vaccine and allergy.
Apart from being a carrier nano-particle and immune modulator, the Siosomes® platform can provide IP protection to unpatentable compounds, such as natural ingredients and biosimilars. The Company intends to further extend its strategic partnerships in the hope of developing a larger product pipeline, particularly in the areas of therapeutic drugs, vaccines, cosmeceuticals, pesticides/insecticides, active ingredients, herbal remedies, and wound healing. The Company has successfully raised seed capital, grants and generated revenues six (6) month s since its inception.
The 2009 BioSingapore Asia Pacific Biotechnology Awards were given out at the BioSingapore Awards Gala Dinner held during BioMedical Asia 2009 on Tuesday 17 March. These awards are a prestigious accolade for the winners from their peers, for accomplishments in the Life Sciences industry, and for the significant contributions they have made in advancing the sector in the Asia -Pacific region. The criteria with which the Most Innovative Start -up was judged on include the following:
- Time since inception less than 2 years
- Excellent management team
- Intriguing business model
- Secured funding to reach milestones and next round of investment
“The BioSingapore Awards 2009 exemplify the growing economic impact and success of the biomedical industry, not only here in Singapore but throughout the Asia -Pacific region, and the importance of the close collaboration between the regional biotechnology organizations working together in the BioNetwork Asia-Pacific (BNAP),” said Prof Sir David Lane, Chairman, Biomedical Research Council (BMRC), Singapore, who was the keynote speaker at the Awards Gala Dinner. The event was attended by life science conference participants and exhibitors from around the world, as well as by scientific and industry leaders, research institutions, and Singapore government officials responsible for driving the nation’s biomedical development.
Commenting on this year’s nominations, Dr Michael Entzeroth, Chairman, BioSingapore, said, “We believe these companies and individuals represent the best of the many excellent and exciting things going on the region. We were also very pleased to see a significant increase in entries this year, which shows a growing interest in the awards. Our judges had some difficult decisions, but are very satisfied with the winners. As the sector grows in our region, we look forward to having an even larger selection to choose from next year!”
Every year, BioSingapore receives nominations from biotechnology industry associations (BNAP), industry peers, academics and institutions across Asia-Pacific for the most outstanding companies or individuals in various categories. The nominees are judged by a panel of distinguished leaders in the field. This year, the judging panel consisted of Dr Anna Lavelle (CEO a nd Executive Director, AusBiotech), Dr Shrikumar Suryanarayan (Director General, Association of Biotechnology -Led Enterprises of India), Dr Jonghoon Choi (Secretary General, Korea Biotechnology Industry Organisation) and Dr Michael Entzeroth.
